113 filings
Page 4 of 6
8-K
25qo56kd4e
31 Jul 20
Submission of Matters to a Vote of Security Holders
8:43am
8-K
zc7od3l1acqykq2sxmp4
28 Jul 20
Novan President and CEO, Paula Brown Stafford Named Chairman of the Board
8:09am
8-K
edsn7kkfssgv0qt
22 Jul 20
Entry into a Material Definitive Agreement
7:05am
8-K
2j23td8atqrp
16 Jul 20
Termination of a Material Definitive Agreement
4:45pm
8-K
607ip0a7y1b94x
9 Jul 20
Other Events
4:45pm
8-K
82fwxz1e9vnv6
25 Jun 20
Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial
8:07am
8-K
pw2gox0it cqiw
16 Jun 20
Entry into a Material Definitive Agreement
9:44pm
8-K
vt4j1ht
15 May 20
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
8:01am
8-K
jayft9mypjf ijqfnz2i
23 Apr 20
Entry into a Material Definitive Agreement
4:49pm
8-K
3bj7 8uq99sx2cyev
3 Apr 20
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
8:21am
8-K
6t6g1
26 Mar 20
Entry into a Material Definitive Agreement
4:16pm
8-K
yyvjdpcc fn7qrx67
23 Mar 20
Novan Announces Data from B-SIMPLE Week 24 Safety Evaluation and COVID-19 Business Updates
8:20am
8-K
dbohxyk qnusndtr
3 Mar 20
Entry into a Material Definitive Agreement
4:18pm
8-K
qsk73qe5av6kph
6 Feb 20
Novan Provides SB206 Program and Business Update
8:36am
8-K
8jm7grh 500zbt
4 Feb 20
Departure of Directors or Certain Officers
4:17pm
8-K
89o2ki8fg92yar02rr
3 Jan 20
Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum
8:13am
8-K
5kwzud
18 Dec 19
Novan Announces Planned Chief Executive Officer Transition
8:05am
8-K
66ofvthlu 490lm6
5 Sep 19
Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
6:36am
8-K
z6vyf
6 Aug 19
Departure of Directors or Certain Officers
4:34pm
8-K
ztkye6a4wih 29
9 May 19
Novan Completes Funding Transaction with Ligand Pharmaceuticals
4:17pm